DE2110488A1 - Mittel zur Induzierung einer fruehzeitigen,langanhaltenden und erhoehten Immunitaet sowie Verfahren zur Induzierung der Antikoerperbildung durch Verwendung dieses Mittels - Google Patents
Mittel zur Induzierung einer fruehzeitigen,langanhaltenden und erhoehten Immunitaet sowie Verfahren zur Induzierung der Antikoerperbildung durch Verwendung dieses MittelsInfo
- Publication number
- DE2110488A1 DE2110488A1 DE19712110488 DE2110488A DE2110488A1 DE 2110488 A1 DE2110488 A1 DE 2110488A1 DE 19712110488 DE19712110488 DE 19712110488 DE 2110488 A DE2110488 A DE 2110488A DE 2110488 A1 DE2110488 A1 DE 2110488A1
- Authority
- DE
- Germany
- Prior art keywords
- sulfate
- inducing
- polymers
- early
- esters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 10
- 230000001965 increasing effect Effects 0.000 title claims description 10
- 230000001939 inductive effect Effects 0.000 title claims description 9
- 238000000034 method Methods 0.000 title claims description 9
- 230000036039 immunity Effects 0.000 title claims description 6
- 230000005923 long-lasting effect Effects 0.000 title claims description 6
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 13
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 229960000633 dextran sulfate Drugs 0.000 claims description 6
- -1 sulfate ester Chemical class 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000007123 defense Effects 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 12
- 229920000447 polyanionic polymer Polymers 0.000 description 11
- 230000004044 response Effects 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- DFCAFRGABIXSDS-UHFFFAOYSA-N Cycloate Chemical compound CCSC(=O)N(CC)C1CCCCC1 DFCAFRGABIXSDS-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19712110488 DE2110488A1 (de) | 1971-03-02 | 1971-03-02 | Mittel zur Induzierung einer fruehzeitigen,langanhaltenden und erhoehten Immunitaet sowie Verfahren zur Induzierung der Antikoerperbildung durch Verwendung dieses Mittels |
| ZA721224A ZA721224B (en) | 1971-03-02 | 1972-02-24 | Pharmaceutical preparations and immunizing systems for inducing an immunity,method of inducing an antibody foration and process for the manufacture of antisera |
| ES400162A ES400162A1 (es) | 1971-03-02 | 1972-02-25 | Procedimiento para la preparacion de un agente para la in- duccion de una inmunidad precoz, largamente duradera y acre-centada. |
| IL38861A IL38861A0 (en) | 1971-03-02 | 1972-02-29 | Pharmaceutical preparations and immunizing systems for inducing an antibody formation and process for the manufacture of antisera |
| FR7207042A FR2128467A1 (en) | 1971-03-02 | 1972-03-01 | Agents for inducing immune response - contg sulphate esters of polymers and reduced amounts of antigen |
| AT174972A AT312801B (de) | 1971-03-02 | 1972-03-02 | Verfahren zur Gewinnung von Antiseren |
| NL7202806A NL7202806A (enExample) | 1971-03-02 | 1972-03-02 | |
| BE780131A BE780131A (fr) | 1971-03-02 | 1972-03-02 | Produit d'induction d'une immunite rapide, prolongee et elevee,et son utilisation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19712110488 DE2110488A1 (de) | 1971-03-02 | 1971-03-02 | Mittel zur Induzierung einer fruehzeitigen,langanhaltenden und erhoehten Immunitaet sowie Verfahren zur Induzierung der Antikoerperbildung durch Verwendung dieses Mittels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2110488A1 true DE2110488A1 (de) | 1972-09-07 |
Family
ID=5800577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712110488 Pending DE2110488A1 (de) | 1971-03-02 | 1971-03-02 | Mittel zur Induzierung einer fruehzeitigen,langanhaltenden und erhoehten Immunitaet sowie Verfahren zur Induzierung der Antikoerperbildung durch Verwendung dieses Mittels |
Country Status (8)
| Country | Link |
|---|---|
| AT (1) | AT312801B (enExample) |
| BE (1) | BE780131A (enExample) |
| DE (1) | DE2110488A1 (enExample) |
| ES (1) | ES400162A1 (enExample) |
| FR (1) | FR2128467A1 (enExample) |
| IL (1) | IL38861A0 (enExample) |
| NL (1) | NL7202806A (enExample) |
| ZA (1) | ZA721224B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447859A (en) * | 1993-07-16 | 1995-09-05 | Viagene | Method for the purification or removal of retroviruses using sulfated cellulose |
| GB0000001D0 (en) * | 2000-01-05 | 2000-02-23 | Du Pont Uk | Pharmaceutical compositions and their preparation |
| US10456464B2 (en) | 2014-08-04 | 2019-10-29 | Nitto Denko Corporation | Liquid immunity induction-promoting composition and vaccine pharmaceutical composition that include thrombosis treatment drug |
-
1971
- 1971-03-02 DE DE19712110488 patent/DE2110488A1/de active Pending
-
1972
- 1972-02-24 ZA ZA721224A patent/ZA721224B/xx unknown
- 1972-02-25 ES ES400162A patent/ES400162A1/es not_active Expired
- 1972-02-29 IL IL38861A patent/IL38861A0/xx unknown
- 1972-03-01 FR FR7207042A patent/FR2128467A1/fr active Granted
- 1972-03-02 NL NL7202806A patent/NL7202806A/xx unknown
- 1972-03-02 AT AT174972A patent/AT312801B/de not_active IP Right Cessation
- 1972-03-02 BE BE780131A patent/BE780131A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AT312801B (de) | 1974-01-25 |
| FR2128467B1 (enExample) | 1975-02-07 |
| FR2128467A1 (en) | 1972-10-20 |
| ES400162A1 (es) | 1974-12-16 |
| NL7202806A (enExample) | 1972-09-05 |
| BE780131A (fr) | 1972-09-04 |
| IL38861A0 (en) | 1972-04-27 |
| ZA721224B (en) | 1972-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69032833T2 (de) | Diagnose und behandlung von insulinabhängigem diabetes mellitus | |
| DE2528411C2 (enExample) | ||
| DE69413024T2 (de) | Verfahren zur herstellung von immunogenen oder diagnostischen reagentien und ebensolche | |
| DE3781078T2 (de) | Verwendunng eines peptids zur herstellung von zusammensetzungen fuer die linderung, behandlung und diagnose von autoimmunkrankheiten, insbesondere arthritis, zu diesem peptid analoge verbindungen, mikro-organismen, die dieses peptid oder eine zu diesem peptid analoge verbindung produzieren, als auch pharmazeutische und diagnostische zusammensetzungen und test kits. | |
| DE3200813A1 (de) | "synthetischer impfstoff gegen virusinfektionen" | |
| CH655246A5 (de) | Verfahren zur herstellung von partikeln aus lipoidloeslichen stoffen. | |
| DE3712767A1 (de) | Immunologisches adjuvans | |
| DE109942T1 (de) | Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff. | |
| DE3433339A1 (de) | Zellmembran-proteine, diese enthaltende arzneimittel und verfahren zu ihrer herstellung | |
| DE2638762A1 (de) | Wasserloesliche adjuvantien, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE69232969T2 (de) | Methode zur herstellung von gram-negativen bakteriellen vakzinen | |
| DE2009343B2 (de) | Verwendung von Lysolecithinen als immunologische Adjuvantien | |
| DE3701066A1 (de) | Intravenoes injizierbares immunglobulin mit hohem antikoerpertiter gegenueber dem respiratorischen syncytialvirus, verfahren zu dessen herstellung und pharmazeutische zubereitung, welche dieses enthaelt | |
| DE3636826A1 (de) | Varicella-zoster-immunglobulin mit hohem titer fuer eine intravenoese verabreichung | |
| Lee et al. | STUDIES ON THE MECHANISM OF THE SHWARTZMAN PHENOMENON: ACCELERATED CUTANEOUS REACTIVITY TO BACTERIAL ENDOTOXINS | |
| EP0201004A2 (de) | Polyvalentes Hyperimmunglobulin-Präparat | |
| DE2110488A1 (de) | Mittel zur Induzierung einer fruehzeitigen,langanhaltenden und erhoehten Immunitaet sowie Verfahren zur Induzierung der Antikoerperbildung durch Verwendung dieses Mittels | |
| DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
| DE3122669A1 (de) | "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2" | |
| EP0121752A2 (de) | Verfahren zur Adjuvierung von Vaccinen | |
| CH630807A5 (de) | Verfahren zur herstellung eines antiserums. | |
| DE2214229A1 (de) | Impfstoffpräparat mit Adjuvans | |
| Muramatsu et al. | Cellular kinetics of phagocytic cells in immunized X-irradiated mice | |
| DE2225548C3 (de) | Intravenös verträglicher Impfstoff gegen Staupe- und Hepatite contagiosa canis | |
| DE3221813A1 (de) | Verfahren zur herstellung von reinem hepatitis b oberflaechenantigen aus menschlichem plasma |